Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab
Follows Earlier License And Supply Agreement For Golimumab Biosimilar
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
